Mylan Communications With CMS To Get Outside Review Under EpiPen Settlement
Executive Summary
Corporate integrity agreement requires Mylan to have an independent body review its drug classifications and US best price determinations; settlement resolves claims Mylan misclassified EpiPen to underpay rebates. Sanofi acted as whistleblower in case.
You may also be interested in...
Mallinckrodt Must Publicize Price Increases In Wake Of DOJ Settlement On Medicaid Rebates
Under corporate integrity agreement, Mallinckrodt must post proposed list price increases for Acthar and other non-generic products along with a link to executive compensation. $234m settlement resolves allegations it underpaid Medicaid rebates resulting from Acthar price hikes.
Will FTC Injunction Against Shkreli’s Company Deter Brands From Pursuing Anti-Generic Actions?
Other companies have largely halted practices at issue in the ‘diabolical anticompetitive plan’ undertaken by Shkreli’s former firm. FTC did not challenge the price hike for Daraprim itself, but did cite an effort to block release of sales data and other tactics to discourage generics.
Pfizer Settles $345m EpiPen Consumers Suit, But Viatris Marches On
After “four years of vigorous litigation,” Pfizer has reached a preliminary settlement over allegations that it devised an “illegal scheme” with Viatris’ Mylan “to monopolize the market” for the EpiPen autoinjector device.